Market Overview

U.S. FDA Approves Alexza's ADASUVE for the Acute Treatment of Agitation Associated with Schizophrenia

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE^® (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.  ADASUVE combines Alexza's proprietary Staccato^® delivery system with the antipsychotic drug, loxapine.  The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in rapid systemic delivery and absorption of a drug.  See below for Important Safety Information about ADASUVE, including Boxed Warnings.

Posted-In: News FDA Legal

 

Related Articles (ALXA)

Around the Web, We're Loving...

Get Benzinga's Newsletters